A comprehensive study of oral oncolytic (anti-cancer) drug treatments revealed that while their use is increasingly common, cancer patients frequently face barriers to accessing oral drugs compared to those delivered intravenously in oncology practice settings. Additionally, while oral anti-cancer drugs have advantages such as patient convenience, they require many crucial procedures by cancer treatment professionals — including management of side effects and monitoring for patient compliance but these key services are not reimbursed by Medicare or other payers…

Continued here:
Study: Poor And Inconsistent Reimbursement Of Oral Cancer Drugs Impairs Treatment

You may also like:

• US FDA Approves Rituxan/MabThera For The Most Common Type Of Adult Leukemia
• Predictors Of Positive Surgical Margins After Laparoscopic Robot Assisted Radical Prostatectomy
• Periprostatic Fat Measured On Computed Tomography As A Marker For Prostate Cancer Aggressiveness
• Life’s Smallest Motor, Cargo Carrier Of The Cells, Moves Like A Seesaw
• Novartis Drug Tasigna® Receives FDA Priority Review For Newly Diagnosed Patients With Early-stage Chronic Myeloid Leukemia
• Research Published By Standard Process Inc. Scientists About The Effects Of Dietary Intervention On Cholesterol Levels
• FDA Advisory Committee Supports Use Of Aztreonam For Inhalation Solution For Patients With Cystic Fibrosis
• Nutra Pharma Announces Launch Of Cobroxin, An Over-the-Counter (OTC) Treatment For Stage 2 (Moderate To Severe) Chronic Pain
• Afinitor® Approved In EU As First Treatment Proven To Benefit Patients With Advanced Kidney Cancer After Failure Of Targeted Therapy
• Merck KGaA Presented New Data On The Combination Of Erbitux With Standard First-Line Therapy In Patients With NSCLC